Implications of Recent Clinical Trials on Pay-for-Performance

Published in: American journal of health-system pharmacy, v. 66, no. 9, May 2009, p. 864-867

Posted on on December 31, 2008

by Walid F. Gellad, Allan S. Detsky, Niteesh K. Choudhry

Ideally pay-for-performance in chronic diseases would be based on outcomes that really matter to patients, such as death, morbidity, and disability. Instead, many of the quality metrics used in pay-for-performance address process measures (e.g., the percentage of diabetic patients who receive glycosylated hemoglobin [HbA1c] testing or a lipid profile each year). The few measures that attempt to address clinical outcomes actually measure surrogate markers like HbA1c, low-density-lipoprotein (LDL) cholesterol, and blood pressure.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.